Type 2 diabetes is the most common type of diabetes. It occurs when your blood has high levels of sugar, also known as glucose. This can cause your pancreas, which is the organ that produces insulin, ...

If you have type 2 diabetes, your doctor might suggest Soliqua 100/33 as a treatment option for you. Soliqua 100/33 comes as a solution that’s injected under your skin. This article describes the ...

Sanofi Announces Soliqua(TM) 100/33 Now Available in the U.S. Paris, France - January 4, 2017 - Sanofi announced today that Soliqua(TM) 100/33 (insulin glargine 100 Units/mL & lixisenatide * 33 mcg/mL ...

Soliqua 100/33 is a brand-name prescription medication. It’s used with diet and exercise to improve blood sugar levels in adults with type 2 diabetes. Soliqua 100/33 contains two drugs: insulin ...

If you have type 2 diabetes, your doctor might suggest Soliqua 100/33 (insulin glargine and lixisenatide) as a treatment option for you. Knowing the possible side effects of this drug can help you and ...

Soliqua 100/33 (insulin glargine/lixisenatide) is a brand-name injection pen that’s prescribed to improve blood sugar levels in adults with type 2 diabetes. The drug’s cost, with and without insurance ...

Sanofi announced the launch of Soliqua 100/33 (insulin glargine and lixisenatide injection) for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin ( Sanofi announced ...

After 30 weeks, least squares (LS) mean reductions in HbA1c for the Soliqua 100/33 treatment groups were 1.09%, 1.44% and 2.41%, respectively. After 30 weeks of treatment, Soliqua 100/33 (insulin ...

In December 2016, Zealand received the $ 25 million milestone payment triggered by the FDA approval of Soliqua 100/33 Copenhagen, 4 January 2017 - Zealand Pharma (Zealand) reports that Sanofi ...